Biohaven .(US:BHVN) Benzingaยท2024-11-25 13:32Core Viewpoint - U.S. stock futures are up, with Dow futures increasing by over 300 points, while shares of Cassava Sciences fell sharply after disappointing Phase 3 study results for Simufilam in Alzheimer's patients [1]. Company Summaries - Cassava Sciences, Inc. experienced a significant decline in share price, dropping 85.6% to $3.82 in pre-market trading following the announcement that Simufilam did not show a significant reduction in cognitive decline compared to placebo in the ReThink-ALZ Phase 3 study [2][1]. - Centessa Pharmaceuticals PLC saw its shares tumble 12% to $15.00 in pre-market trading after reporting a quarterly loss of $0.37 per share [4]. - Biohaven Ltd. shares fell 11% to $40.60 after the treatment arm of the RESILIENT SMA study did not statistically separate from the placebo group at Week 48 [4]. - ZIM Integrated Shipping Services Ltd. shares dipped 6.9% to $22.15 despite reporting better-than-expected third-quarter financial results and raising FY24 adjusted EBIT and EBITDA guidance [4]. - i3 Verticals, Inc. shares declined 6.6% to $22.11 after posting disappointing quarterly results [4]. - ChromaDex Corporation shares fell 5.9% to $7.00 in pre-market trading [4]. - Fitell Corporation shares declined 4.9% to $24.00 after gaining around 6% on the previous trading day [4]. - Logility Supply Chain Solutions, Inc. shares fell 4.4% to $9.31 after reporting worse-than-expected second-quarter revenue results and issuing FY25 revenue guidance below estimates [4]. - Kingsoft Cloud Holdings Limited shares fell 4.3% to $6.90 after a significant jump of around 25% on the previous trading day, despite reporting a fiscal third-quarter 2024 revenue of 1.89 billion Chinese yuan ($268.7 million), which was up 16.0% year-on-year and exceeded analyst expectations [4].